Market Spotlight: Cold Agglutinin Disease
|出版日期||內容資訊||英文 23 Pages
|市場聚光燈:冷血球凝集素症 (CAD) Market Spotlight: Cold Agglutinin Disease|
|出版日期: 2020年08月20日||內容資訊: 英文 23 Pages|
本報告提供全球冷血球凝集素症 (CAD) 治療藥市場相關調查分析，疾病的背景、治療資訊，主要開發平台藥物、臨床實驗，成功的概率，許可證、收購交易，流行病學概要相關的系統性資訊。
This Market Spotlight report covers the Cold Agglutinin Disease market, comprising key pipeline drugs, clinical trials, probability of success, and an epidemiology overview.
There are only three industry-sponsored drugs in active clinical development for cold agglutinin disease, with one drug each in Phase I, Phase II, and the NDA/BLA phase.
Therapies in development for cold agglutinin disease target the complement pathway. These pipeline drugs are administered via the intraocular, subretinal, subconjunctival, intravenous, and subcutaneous routes.
The overall likelihood of approval of a Phase I autoimmune/immunology-other asset is 21.8%, and the average probability a drug advances from Phase III is 70.2%. Drugs, on average, take 9.8 years from Phase I to approval, compared to 9.0 years in the overall autoimmune/immunology space.
The distribution of clinical trials across Phase I-III indicates that the majority of trials for cold agglutinin disease have been in the early and mid-phases of development, with 67% of trials in Phase I-II, and 33% in Phase III.
The majority of clinical trial activity in the cold agglutinin disease space comprises completed trials.
Sanofi leads industry sponsors with the highest number of clinical trials for cold agglutinin disease